Csl Behring LLC
Biotherapeutic company providing recombinant and plasma-derived products.
Based in PA
🤖
AI Overview
With $1.4M in lobbying spend across 28 quarterly filings, Csl Behring LLC is a significant lobbying presence.
$1.4M
Total Lobbying Spend
28
Quarterly Filings
1
Lobbying Firms Used
9
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2019 | $200K |
| 2020 | $350K |
| 2021 | $150K |
| 2022 | $150K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $150K |
Lobbying Firms
THE NICKLES GROUP, LLC
What They Lobby For
- Orphan Drug Act, Medicare payment for home infusion services, drug importation, drug pricing proposals included in Administration's Blueprint "America's Patients First" a plan to lower prescription drug prices.
- Issues related to home infusion and DME self-administered therapies. Issues regarding reimbursement of drugs, biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list.
- Issues related to orphan drug tax credit.
- Monitored issues related to prescription drug pricing.
- Monitored issues related to the conference report accompanying H.J. Res 31.
- Monitored issues related to prescription drug pricing. H.R. 2296, FAIR Drug Pricing Act of 2019. Monitored S. 1895, Lower Health Care Costs Act of 2019, as it relates to pricing transparency and drug pricing. H.R. 2113, Prescription Drug STAR Act.
- Issues related to home infusion and DME self-administered therapies. Issues regarding reimbursement of drugs, biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list. H.R. 2296, FAIR Drug Pricing Act of 2019. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. H.R. 2113, Prescription Drug STAR Act.
- Monitored issues related to prescription drug pricing. H.R. 2296, the METRIC Act. Monitored S. 1895, Lower Health Care Costs Act of 2019, as it relates to pricing transparency and drug pricing. H.R. 2113, Prescription Drug STAR Act.
- Issues related to home infusion and DME self-administered therapies. Issues regarding coverage reimbursement of biologics and plasma therapies. Issues pertaining to drugs listed on the Self-Administered Drug list. H.R. 2296, the METRIC Act. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. H.R. 2113, Prescription Drug STAR Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019.
- Monitored H.R. 4378, the Continuing Appropriations Act of 2020 and Health Extenders Act of 2019.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.